Pokerchips. I think the answer to your question of why you think Nolupus has a fondness for quicksand lies in his pseudonym. I think he believes that Lupus is not a disease with a single causal fa for which an cure will be eventually discovered. Instead, I think he holds the plausible view that Lupus is a syndrome which consists of different causal factors that make the person's immune system turn in upon itself and attack healthy organs of the body causing severe inflammation which may be fatal. There is not necessarily any single cure for this because although the symptoms are similar their origins are different. Probably the most we can hope for at present is various therapeutic treatments like steroids which reduce the harmful symptoms such as excessive inflammation. So Lupuzor may turn out to ineffective against many of the symptoms that carry the Lupus label but effective against others because they have a different causal origin. That is why Nolupus has always seemed to be a Cassandra figure and perhaps he will be justified in the end. I hope not!
alphacharlie77 I'm in same position as you. Have given up averaging down. A mug's game? Kind of given up hope. But hanging on for a favourable FDA agreement for Phase 3 and other positive news on the IMM pipeline.
Nolupus. Thanks for the link. V interesting. If these immunologists are correct we are entering a post Covid-19 environment where IMM's therapeutic drugs have an important role if they are as effective as IMM's scientists claim.
Icarus; I agree - the current sp represents a realistic risk/reward level for IMM. It is interesting that there is support for the 9p level despite the lack of news from the Board. I guess that many investors like me are banking on a positive response from FDA in this quarter to the PK info from IMM that they requested.
Dallo. 40p would signal failure. What is the hurry to sell the company? The costs of the Phase 3 trial will be covered by Avion and there are several drugs in the IMM pipeline due to come to market in late 2022 and 2023 with funding assured for a further 2 years. I doubt if Dr Zimmer would accept such a low price.
Completion date of Lupuzor Phase 3 trial21 Apr 2021 21:50
I don't know why Nolupus and others have not quoted the estimate for completion of the Lupuzor Phase 3 trial provided by the COO, Tim Franklin, in his presentation to the US Biotech Showcase in January 2021, namely 2H 2022. Surely he knows more about it than any of the "experts" on this BB, doesn't he?
I'll be sorry to see you leave when the SP reaches 12.5p. You have invested very perspicaciously to have achieved such a low average investing price. To achieve that, I need a price of more than three times higher, so if I want to at least breakeven I have to stick around a lot longer. In fact, if the news is good enough to justify that higher breakeven level, I'll stick around longer 'cos I have a deep conviction that Lupuzor will be the answer to the prayers of Lupus victims.
Nolupus, you say you are expecting a TR1 (notification of change in a major share holding) from Lanstead or Zimmer soon. I'm no expert, but the huge amount of buying and selling that has been going on this week does not remind me of them, or certainly not Zimmer. The trades we've been seeing are evidence of traders taking advantage of pricing anomalies in IMM's shares, and they make no pretence of it. Take one lot of shares and their are several examples that I could give. 103,159 shares bought at 09:20:41 @8.7205 total cost £8996. 103,159 shares sold at 09:28:42 @8.8859 total receipt £9280. Trader's profit: £284. Repeated over the trading day = a few thousand £s for the trader. This may be suggestive of Lanstead's trading pattern. But I'm sure it is not of Zimmer - I don't see him as a ST trader. I expect him to hold as President and Chief Science Officer of IMM because he knows what is in the pipeline.